false000172312800017231282023-05-092023-05-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 9, 2023
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3848532-0546926
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareAMRXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07
Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) on May 9, 2023. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:
Proposal 1: To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified:
 
 
For
 
 
Against
 
 
Abstain
 
 
Broker Non-Votes
 
Emily Peterson Alva
 
 
229,279,380
1,816,706
96,495
25,513,061
 
Deb Autor
 
 
229,602,211



1,483,770


106,600



25,513,061
 
J. Kevin Buchi


197,910,568



33,179,505


102,508



25,513,061

Jeff George
 
 
198,211,840



32,879,658


101,083



25,513,061
 
John Kiely
 
 
196,066,358



35,022,385


103,838



25,513,061
 
Paul Meister
 
 
212,151,263


18,932,673


108,645



25,513,061
 
Ted Nark
 
 
228,742,967



2,217,364


232,250



25,513,061
 
Chintu Patel
 
 
229,230,849



1,865,246


96,486



25,513,061
 
Chirag Patel
 
 
229,182,342



1,913,165


97,074



25,513,061
 
Gautam Patel
 
 
227,239,534



3,785,347


167,700



25,513,061

Shlomo Yanai
 
 
229,147,164



1,938,034


107,383



25,513,061
 

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:
For
 
Against
 
Abstain
 
Broker Non-Votes
227,413,821
3,098,184
680,576
25,513,061

Proposal 3: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023:
For
 
Against
 
Abstain
 
Broker Non-Votes
254,931,713

1,641,294
132,635

0

Proposal 4: To approve the Amended & Restated 2018 Incentive Award Plan:
For
 
Against
 
Abstain
 
Broker Non-Votes
215,730,063

15,006,306
456,212

25,513,061






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 12, 2023
AMNEAL PHARMACEUTICALS, INC.
By:/s/ Jason B. Daly
Name:Jason B. Daly
Title:Executive Vice President, Chief Legal Officer and Corporate Secretary